Essen, Germany. Evonik records a strong business performance in the second quarter. Consequently, the company is raising its forecast for the financial year 2026 considerably.
Based on preliminary figures, Evonik expects an adjusted EBITDA between €600 million and €650 million for the second quarter, representing a 23 percent increase compared to the prior-year results (Q2 2025: €509 million) at the mid-point. At the beginning of May, Evonik had forecasted earnings of at least €550 million for the second quarter.
This positive earnings development is driven by both higher sales volumes and higher prices, alongside ongoing cost reductions. In the Advanced Technologies segment specifically, Evonik is benefiting from supply chain disruptions affecting Asian competitors who are currently facing raw material supply limitations.
This favorable situation is expected to weaken later in the year as global marine shipping stabilizes following the reopening of the Strait of Hormuz. As a result, uncertainties persist for the second half of the year. In the Animal Nutrition segment, however, Evonik currently expects that the positive momentum will continue into the third quarter.
According to preliminary figures, adjusted EBITDA for the first half of 2026 is expected to be around €1.1 billion.
Based on these developments, Evonik is considerably raising its outlook for the fiscal year 2026. The company now expects adjusted EBITDA to range between €2.0 billion and €2.2 billion (previously: €1.7 billion to €2.0 billion). In 2025, Evonik earned around €1.9 billion.
Regarding free cash flow, Evonik continues to target a cash conversion rate of around 40 percent (2025: 37 percent). Free cash flow in the second quarter is expected to be significantly better than in the prior year (Q2 2025: minus €211 million).
Against the backdrop of ongoing structural challenges in the chemical industry, Evonik is consistently advancing its transformation efforts. As announced on June 18, the "Evonik Tailor Made" program will be extended and expanded. It includes additional structural and efficiency measures in administration and operating units. As part of "Evonik Tailor Made" and other efficiency programs in the business lines, 2,800 jobs are being cut between 2024 and 2026. An additional reduction of around 3,200 jobs is planned for 2027 to 2029. The program aims to sustainably improve the company’s cost structure to enhance long-term competitiveness.
Evonik is scheduled to publish final figures for the second quarter on August 4, 2026.